SLC22A2 and renal cell carcinoma: Human organic cation transporter 2 (OCT2) abnormalities confer renal cell carcinoma (RCC) increased resistance to chemotherapeutic agents such as oxaliplatin (OXA) and decitabine (DAC) under hypoxic conditions [167, 168].